EcoDrugPlus

Cyclin Dependent Kinase 4

Ensembl ID : ENSCABG00000007696
Gene Symbol: CDK4
1 Cross references
239 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 6

Ensembl ID : ENSCABG00000002824
Gene Symbol: CDK6
1 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 7

Ensembl ID : ENSCABG00000020808
Gene Symbol: CDK7
1 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cyclin Dependent Kinase 9

Ensembl ID : ENSCABG00000001804
Gene Symbol: CDK9
1 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSCABG00000005632
Gene Symbol: CYSLTR1
1 Cross references
181 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytidine Deaminase

Ensembl ID : ENSCABG00000020299
Gene Symbol: CDA
1 Cross references
232 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 17 Subfamily A Member 1

Ensembl ID : ENSCABG00000015403
Gene Symbol: CYP17A1
1 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSCABG00000012227
Gene Symbol: CYP19A1
1 Cross references
318 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSCABG00000013662
Gene Symbol: CYP26A1
1 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSCABG00000016564
Gene Symbol: CYP46A1
1 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSCABG00000018644
Gene Symbol: DGAT1
1 Cross references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSCABG00000020741
Gene Symbol: DDR2
1 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).